Literature DB >> 16261918

Comparison of antibiotic use between an 'open' and a 'closed' intensive care unit.

E M Murunga1, M Reriani, C F Otieno, N M Wanyoike.   

Abstract

OBJECTIVE: To determine differences in antibiotic use between a 'closed' ICU in a hospital in Israel and an 'open' ICU in a Kenyan hospital.
DESIGN: Retrospective comparative study.
SETTING: The ICU of Beilinson hospital in Rabin Medical Centre, Tel Aviv, Israel and the ICU of Mater Hospital, Nairobi Kenya.
SUBJECTS: One hundred and forty patients from Beilinson and one hundred fifty one patients from Mater Hospital were enroled. MAIN OUTCOME MEASURES: Antibiotic use in the different ICU settings.
RESULTS: Seven different antibiotics namely Erythromycin, Meropenem, Taxobactam/Piperacillin, Metronidazole, Gentamycin, Ceftriaxone and Cefuroxime were used in sufficient numbers in both centres to allow for statistical analysis. Four of these seven namely metronidazole, gentamycin, ceftriaxone and cefuroxime demonstrated statistically significant difference between the two centres.
CONCLUSION: The level, of antibiotic use is demonstrably higher in 'open' ICUs with fewer controls to antibiotic prescriptions than in 'closed' ICUs with stricter control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261918     DOI: 10.4314/eamj.v82i8.9326

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  3 in total

Review 1.  Intensive care unit capacity in low-income countries: a systematic review.

Authors:  Srinivas Murthy; Aleksandra Leligdowicz; Neill K J Adhikari
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

2.  The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use.

Authors:  Niaz Al-Somai; Mohammed Al-Muhur; Osama Quteimat; Nashaat Hamzah
Journal:  Saudi Pharm J       Date:  2014-02-26       Impact factor: 4.330

3.  Antimicrobial resistance among children in sub-Saharan Africa.

Authors:  Phoebe C M Williams; David Isaacs; James A Berkley
Journal:  Lancet Infect Dis       Date:  2017-10-09       Impact factor: 25.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.